Загрузка...
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...
Сохранить в:
| Опубликовано в: : | Biomedicines |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168248/ https://ncbi.nlm.nih.gov/pubmed/32019149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8020022 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|